Randi Isaacs

6.3k total citations
41 papers, 1.6k citations indexed

About

Randi Isaacs is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Randi Isaacs has authored 41 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Molecular Biology and 8 papers in Hematology. Recurrent topics in Randi Isaacs's work include Fibroblast Growth Factor Research (9 papers), Metastasis and carcinoma case studies (5 papers) and CAR-T cell therapy research (4 papers). Randi Isaacs is often cited by papers focused on Fibroblast Growth Factor Research (9 papers), Metastasis and carcinoma case studies (5 papers) and CAR-T cell therapy research (4 papers). Randi Isaacs collaborates with scholars based in United States, France and Switzerland. Randi Isaacs's co-authors include Daniel J. Skiest, José A. Vázquez, Sanela Bilic, Leslie Oleksowicz, Janice P. Dutcher, Suman Sen, Elena Puszkin, John D. Baxter, Navdeep Boparai and Jagadish Gogate and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Randi Isaacs

41 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Randi Isaacs United States 22 588 582 309 276 252 41 1.6k
Patrick Lutz France 26 374 0.6× 490 0.8× 477 1.5× 492 1.8× 372 1.5× 62 2.3k
Holger W. Auner United Kingdom 24 677 1.2× 619 1.1× 285 0.9× 566 2.1× 129 0.5× 87 1.7k
Stavros Rafail United States 22 966 1.6× 554 1.0× 259 0.8× 331 1.2× 200 0.8× 33 2.4k
Ângelo Maiolino Brazil 26 512 0.9× 802 1.4× 610 2.0× 820 3.0× 563 2.2× 110 2.3k
Huifang Lu United States 17 310 0.5× 418 0.7× 168 0.5× 296 1.1× 157 0.6× 58 2.0k
Kazuyuki Matsuda Japan 22 498 0.8× 359 0.6× 139 0.4× 370 1.3× 136 0.5× 114 1.6k
Joseph M. Wiley United States 19 302 0.5× 338 0.6× 200 0.6× 630 2.3× 202 0.8× 37 1.5k
Esa Jantunen Finland 23 239 0.4× 861 1.5× 569 1.8× 300 1.1× 343 1.4× 73 2.0k
D Niethammer Germany 21 392 0.7× 282 0.5× 176 0.6× 399 1.4× 85 0.3× 96 1.5k
Yuko Osugi Japan 23 379 0.6× 546 0.9× 365 1.2× 773 2.8× 348 1.4× 48 2.0k

Countries citing papers authored by Randi Isaacs

Since Specialization
Citations

This map shows the geographic impact of Randi Isaacs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Randi Isaacs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Randi Isaacs more than expected).

Fields of papers citing papers by Randi Isaacs

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Randi Isaacs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Randi Isaacs. The network helps show where Randi Isaacs may publish in the future.

Co-authorship network of co-authors of Randi Isaacs

This figure shows the co-authorship network connecting the top 25 collaborators of Randi Isaacs. A scholar is included among the top collaborators of Randi Isaacs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Randi Isaacs. Randi Isaacs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Moser, Justin C., Mateusz Opyrchal, Brendan D. Curti, et al.. (2024). A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab.. Journal of Clinical Oncology. 42(16_suppl). 2623–2623. 2 indexed citations
2.
Cummins, Katherine D., Noelle V. Frey, Anne Marie Nelson, et al.. (2017). Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells. Blood. 130. 1359–1359. 92 indexed citations
3.
Isaacs, Randi, et al.. (2016). Mixed acinar-endocrine carcinoma of the pancreas. HPB. 18. e380–e380. 1 indexed citations
4.
Jain, Apurva, Rachna T. Shroff, Robin Kate Kelley, et al.. (2016). FGFR pathway genetic aberrations in cholangiocarcinoma: Demographics and experience with targeted therapy.. Journal of Clinical Oncology. 34(15_suppl). 109–109. 7 indexed citations
5.
Meyer, Matthew J., David F. Jenkins, David Batt, et al.. (2015). Abstract 1680: In vitro and in vivo activity of a highly potent and novel FGFR2/FGFR4 dual targeting antibody-drug conjugate. Cancer Research. 75(15_Supplement). 1680–1680. 4 indexed citations
6.
Iyer, Swaminathan P., A. Keith Stewart, Jatin J. Shah, et al.. (2014). A Phase IB multicentre dose‐determination study of BHQ880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal‐related events. British Journal of Haematology. 167(3). 366–375. 120 indexed citations
7.
Sequist, Lecia V., Andréa Varga, Josep Tabernero, et al.. (2014). Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. Kölner Universitäts PublikationsServer (Universität zu Köln). 29 indexed citations
8.
Sequist, Lecia V., Andréa Varga, Josep Tabernero, et al.. (2014). Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. Cancer Research. 74(19_Supplement). CT326–CT326. 68 indexed citations
9.
Skiest, Daniel J., José A. Vázquez, Gregory M. Anstead, et al.. (2007). Posaconazole for the Treatment of Azole-Refractory Oropharyngeal and Esophageal Candidiasis in Subjects with HIV Infection. Clinical Infectious Diseases. 44(4). 607–614. 111 indexed citations
10.
11.
Vázquez, José A., Daniel J. Skiest, Leonardo Nieto, et al.. (2006). A Multicenter Randomized Trial Evaluating Posaconazole versus Fluconazole for the Treatment of Oropharyngeal Candidiasis in Subjects with HIV/AIDS. Clinical Infectious Diseases. 42(8). 1179–1186. 128 indexed citations
12.
13.
Preti, Robert A., et al.. (1998). CD34+CD33- cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients.. Journal of Clinical Oncology. 16(6). 2093–2104. 50 indexed citations
14.
O’Byrne, Kenneth J., et al.. (1998). Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer. British Journal of Cancer. 77(11). 1950–1956. 9 indexed citations
15.
Oleksowicz, Leslie, et al.. (1996). Alterations in Platelet Function in Patients Receiving Interleukin-6 as Cytokine Therapy. Cancer Investigation. 14(4). 307–316. 7 indexed citations
16.
Weiss, Geoffrey R., Kim Margolin, Mario Sznol, et al.. (1995). A Phase II Study of the Continuous Intravenous Infusion of Interleukin-6 for Metastatic Renal Cell Carcinoma. Journal of Immunotherapy. 18(1). 52–56. 13 indexed citations
17.
Isaacs, Randi. (1995). Advances in the Treatment of Breast Cancer: Balancing Technology and Economics. Journal of women's health. 4(1). 15–26. 1 indexed citations
18.
Isaacs, Randi, et al.. (1993). In the absence of other Fc receptors, Fc gamma RIIIA transmits a phagocytic signal that requires the cytoplasmic domain of its gamma subunit.. Journal of Clinical Investigation. 92(4). 1967–1973. 48 indexed citations
19.
Isaacs, Randi, Paul R. Findell, Pamela L. Mellon, Charles Branch Wilson, & John D. Baxter. (1987). Hormonal Regulation of Expression of the Endogenous and Transfected Human Growth Hormone Gene. Molecular Endocrinology. 1(8). 569–576. 30 indexed citations
20.
Slater, Emily P., Thomas R. Anderson, Peter A. Cattini, et al.. (1986). Mechanisms of Glucocorticoid Hormone Action. Advances in experimental medicine and biology. 196. 67–80. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patrick Lutz Breakdown of academic impact, for papers by Holger W. Auner Breakdown of academic impact, for papers by Stavros Rafail Breakdown of academic impact, for papers by Ângelo Maiolino Breakdown of academic impact, for papers by Huifang Lu Breakdown of academic impact, for papers by Kazuyuki Matsuda Breakdown of academic impact, for papers by Joseph M. Wiley Breakdown of academic impact, for papers by Esa Jantunen Breakdown of academic impact, for papers by D Niethammer Breakdown of academic impact, for papers by Yuko Osugi
Rankless by CCL
2026